Roth Capital’s Bold Predictions: GeoVax Labs Q3 Earnings and Beyond
In a significant development for the biotech sector, Roth Capital has recently adjusted its third-quarter 2025 earnings per share (EPS) estimates for GeoVax Labs Inc. This revision…
Roth Capital Cuts GeoVax Labs’ FY2028 EPS Amidst Mixed Analyst Outlook
The financial landscape for GeoVax Labs Inc. recently saw a notable shift as equities research analysts at Roth Capital adjusted their future earnings projections for the biotech…